Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/20/2021 | $4.00 | Speculative Buy | Benchmark |
MELBOURNE, Australia and SAN FRANCISCO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, announced the appointment of Abby Macnish Niven as the Company's Chief Financial Officer (CFO), effective today. "We look forward to Abby's contributions whose broad experience and financial background will help us advance our programs. I would also like to express my gratitude to Phillip and his team who supported us during a transition period," said David Stamler, M.D., Chief Executive Officer of Alterity. Ms Macnish Niven h
MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Phillip Hains as the Company's new Chief Financial Officer (CFO), effective 31 January 2024. Mr. Hains has served as the Company Secretary of Alterity since 2014, and his experience includes almost 30 years in corporate secretarial, accounting and general management through professional services firm Acclime and predecessor firm The CFO Solution. The appointment of Mr. Hains follows the resignatio
Benchmark initiated coverage of Alterity Therapeutics with a rating of Speculative Buy and set a new price target of $4.00
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)
MELBOURNE, AUSTRALIA and SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the peer-reviewed journal, Metallomics has published data on the importance of iron and iron-targeting agents like ATH434 to treat neurodegenerative diseases. Metallomics publishes cutting-edge investigations that elucidate the dynamics, role, and impact of metals in biological systems. David Stamler, M.D., Chief Executive Officer of Alterity, commented, "Iron has long been implicated in neurodegeneration, bu
Highlights Topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for release in January 2025Positive interim data reported from ATH434-202 Phase 2 clinical trial showing the potential for ATH434 to modify disease progression in Multiple System AtrophyMultiple data presentations at the International Congress of Parkinson's Disease and Movement Disorders® (MDS)Appointed Abby Macnish Niven as Chief Financial OfficerCash balance on 30 September 2024 of A$9.28m MELBOURNE, Australia and SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing dise
MELBOURNE, Australia and SAN FRANCISCO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer of Alterity will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit on Thursday, 17 October 2024 at 1:30 p.m. ET in the United States / Friday, 18 October 2024 at 4:30 a.m. AEDT in Australia. A link to the live and archived webcast may be accessed on the Alterity website under the Investors section: Events and Presentations. An archive of the w
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)
6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)